Skip to content
10-K

Annual Report

Nuvectis Pharma, Inc. NVCT

0001558370-25-001496

← back to feed
Filed
Feb 25, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 21, 2025 23.39M sh
Shares Diluted FY 2024 · Dec 31, 2023 15.56M sh
Operating Cash Flow FY 2024 · Dec 31, 2023 −$15.95M
Cash And Equivalents FY 2024 · Dec 31, 2023 $19.13M
Current Liabilities FY 2024 · Dec 31, 2023 $6.98M
Total Liabilities FY 2024 · Dec 31, 2023 $6.98M
Current Assets FY 2024 · Dec 31, 2023 $19.19M
Total Assets FY 2024 · Dec 31, 2023 $19.19M
Eps Diluted FY 2024 · Dec 31, 2023 −$1.43
Eps Basic FY 2024 · Dec 31, 2023 −$1.43
Sga Expense FY 2024 · Dec 31, 2023 $7.52M
Rd Expense FY 2024 · Dec 31, 2023 $15.38M
Net Income FY 2024 · Dec 31, 2023 −$22.26M
Operating Income FY 2024 · Dec 31, 2023 −$22.9M
Stockholders Equity FY 2024 · Dec 31, 2022 $14.22M